We describe the proportion of health care facility-onset Clostridium difficile infection (HO-CDI) National Healthcare Safety Network laboratory-identified events at our facility that were deemed nontrue HOCDIs. Reasons included testing in a patient without significant diarrhea or with recent laxative use, or delayed testing. Standardized infection ratios using only true HO-CDI in the numerator were improved compared with publically reported standardized infection ratios. A prioritization matrix identifies which clinical services could benefit most from directed diagnostic stewardship interventions.
Laboratory-identified (LabID) Clostridium difficile events are reported publically by the Centers for Disease Control and Prevention National Healthcare Safety Network as a patient safety metric that influences facility reputation and reimbursement. 1 In broad terms, each unique, positive C difficile test, taken after day 3 of hospital admission, constitutes a health care facility-onset C difficile infection (HO-CDI) LabID event. This metric does not incorporate chart review; therefore, it is less labor-intensive and potentially more objective, but influenced by test characteristics and behaviors.
Many microbiology laboratories in the United States use highly sensitive nucleic acid amplification tests to detect C difficile toxin A or B genes. 2 A positive test performed on an asymptomatic patient may represent colonization prevalent in a hospitalized population. 3 Delayed testing of a symptomatic patient, beyond the third day of hospitalization, can lead to misclassification of community-onset infection as HO-CDI. Facility knowledge of what HO-CDI events represent, coupled with interventions to promote appropriate and timely diagnostic testing-known as diagnostic stewardship-can address these issues.
We elucidate the proportion of reportable HO-CDI LabID events at our institution that represent true HO-CDI versus asymptomatic C difficile colonization due to inappropriate testing or community-onset CDI with delayed testing.
METHODS
This study was conducted at The Johns Hopkins Hospital, a 1,000-bed tertiary academic center in Baltimore, MD. Trained infection preventionists (IPs) conducted prospective chart review for each HO-CDI LabID event from January 2015-June 2016. True HO-CDI was defined as clinically significant diarrhea (≥3 episodes in 24 hours) not present on admission, without laxatives administered during the preceding 48 hours. A second retrospective chart review was later conducted for nontrue HO-CDI cases to verify reasons and to ascertain treatment of CDI (metronidazole or vancomycin) within 14 days of positive test. New standardized infection ratios (SIRs) that include only true HO-CDI in the numerator were calculated for each quarter and compared with the publically reported HO-CDI SIR. 4 A prioritization matrix was used to rank services according to potential return on performance improvement investment to direct future diagnostic stewardship interventions. A service that is not contributing many events to the HO-CDI, or a service where tests are mostly appropriate, would likely not be a top priority for intervention. Prioritization matrices are used in other health care domains such as lean sigma and clinical decision support for breast care. 5 Ranking of the raw number of HO-CDI LabID events (service contribution to the HO-CDI) was multiplied by the ranking of percent inappropriate tests (a large proportion of inappropriate tests indicates significant opportunity for improvement). See Table 1 .
RESULTS
There were 490 HO-CDI LabID events during 452,587 patientdays; 284 (58%) were true HO-CDI, whereas 206 (42%) were classified as nontrue (either inappropriate or delayed testing). Reasons for nontrue HO-CDI included no significant diarrhea (n = 94; 49.5%), laxative use within the previous 48 hours (n = 78; 41%), and delayed testing (n = 18; 9.5%). There were 16 charts (7.8%), where retrospective chart review to ascertain specific reason for nontrue HO-CDI was not possible. Of 172 patients with inappropriate testing, 159 (92%) were treated for CDI. For the true HO-CDI, the SIR was below 1 every quarter, compared with 2 of 6 quarters for the publically reported HO-CDI. See Figure 1 .
DISCUSSION
We found that almost half of HO-CDI LabID events at our institution were not true health care facility-onset infections, but due to inappropriate or delayed testing. We recognize that HO-CDI LabID is a proxy for hospital-acquired infections; however, a discrepancy of this proportion is likely not consistent with the intent of the metric. We found true HO-CDI SIRs were substantially lower than the publically reported SIRs, demonstrating how decreasing inappropriate testing could have an influence on a facility's HO-CDI SIR and on reported rates of HO-CDI. Another major finding of this study is that more than 90% of patients with inappropriate testing and apparent C difficile colonization were treated for CDI. This unnecessary antibiotic treatment places these patients at risk for disruption of the intestinal microbiome, other adverse events, or progression to CDI. 5 Diagnostic stewardship interventions can be applied to C difficile testing to ensure more appropriate testing. Diagnostic stewardship is an essential part of antibiotic stewardship, infection prevention, and therapeutic decision making. 6, 7 Potential diagnostic stewardship approaches for C difficile testing include education and electronic medical record best practice alerts to help clinicians avoid ordering a test when a patient has had a recent laxative, or does not have clinically significant diarrhea, thereby increasing the pretest probability of detecting only true C difficile disease. In this study, the prioritization matrix approach identified medicine as a top priority for reduction in inappropriate or delayed testing. Psychiatry was the second priority. Although it did not contribute many HO-CDI LabIDs, a large proportion represented inappropriate or delayed testing, and therefore could have a significant yield from minimal diagnostic stewardship intervention or good return on performance improvement investment. Revision of the HO-CDI LabID metric to include clinical data from chart review would likely increase specificity and more accurately measure true HO-CDI. Enhanced National Healthcare Safety Network LabID risk adjustment for test method (nucleic acid amplification tests, enzyme immunoassay, and all others) might help account for the increased sensitivity of nucleic acid amplification tests. 8 Additional changes to the metric would be required if facilities were to adopt screening and use of contact precautions for asymptomatic C difficile-colonized patients. 9 In the absence of changes to the metric, inflation of the reported HO-CDI could become even more pronounced.
This study has limitations. It was conducted at a single academic center and may not be generalizable to other settings. Charts were not available for retrospective review of 7.7% of nontrue HO-CDI cases to determine the reason; however, it is unlikely that a specific category was systematically excluded. We did not include lack of diarrhea due to paralytic ileus in the HO-CDI definition. However, the simple definition used was conservative and more likely to classify inappropriate tests as appropriate rather than vice versa.
Facilities and jurisdictions seeking to improve reported HO-CDI LabID should investigate what proportion of these HO-CDI LabID events represent true infections and what proportion represent delayed tests or inappropriate tests of asymptomatic, colonized patients. This information will allow for focused improvement efforts that are appropriately targeted infection prevention and antimicrobial stewardship interventions to prevent true C difficile acquisition in health care settings, and diagnostic stewardship interventions to decrease inappropriate and delayed C difficile testing.
